

For Immediate Release

Company Name: Shinsei Corporate Investment Limited
 Name of Representative: Ippei Matsubara
 President and CEO

Final Closing of the Investment Fund for iPS Cell and Regenerative Medicine Venture Businesses

Tokyo (Monday, April 20, 2015) --- Shinsei Corporate Investment, Limited (hereafter “SCI”), today announced that it conducted the final closing of the “Cell Innovation Partners, L.P.” (hereafter “the Fund”) on March 27, 2015, following to the announcement by SCI regarding the launch of operation of the Fund with ReproCELL Inc. (Yokohama-shi, Kanagawa Prefecture; President and CEO Chikafumi Yokoyama; hereafter “ReproCELL”) in the press release issued on September 29, 2014, titled “The Launch of Operation of Cell Innovation Partners, L.P. with ReproCELL, an iPS Cell Bio-Company.”

The Fund was commenced at the size of 800 million yen on September 26, 2014, through an investment by a General Partner (GP), Cell Innovation Partners Limited, which was jointly established by RC Partners Limited, a 100% subsidiary of ReproCELL, and SCI, and through investments by Limited Partners (LPs), ReproCELL, Shinsei Bank, Limited, and SMBC Strategy Series 2 Investment Limited Liability Partnership. The purpose of the Fund is to invest in venture companies inside and outside of Japan that focus on the development of pluripotent cell, including iPS cell, and regenerative medicine technology, in order to enhance research and development in the practical application of regenerative medicine. At the recent final closing, the Fund size totaled 900 million yen with the addition of a new LP investment by another business firm. The participation of the business firm is expected to broaden the range of support that can be provided portfolio companies, as well as support the business firm with advanced technology to enter the areas of iPS cell and regenerative medicine.

The Fund aims to contribute to accelerating the practical application of the next generation of drug discovery and health care businesses by providing growth funds to Japanese and overseas cellular and regenerative medicine venture companies, and will proactively invest in leading cellular and regenerative medicine venture businesses.

SCI has proactively made pre-IPO investments to provide growth funds to middle- and later-stage venture companies, and has established joint funds with partners outside of the Group. Since the iPS cell and regenerative health care areas are part of the medical and healthcare business fields, a focus area of Shinsei Bank Group’s Second Medium-Term Management Plan, SCI will contribute to the development of new business fields through the provision of growth funds.

[Summary of the Fund]

Name	: Cell Innovation Partners, L.P.
Country	: Cayman Islands
Foundation	: March 2014
Fund size	: 900 million yen
Operating company	: Cell Innovation Partners Limited* (URL: http://www.cell-ip.com)
Partners	: General Partner (GP): Cell Innovation Partners Limited* Limited Partners (LP): ReproCELL Incorporated, Shinsei Bank, Limited, SMBC Strategy Series 2 Investment Limited Liability Partnership, and one business firm
Period	: 7 years
Investment target	: iPS cell and regenerative medicine bio-venture companies inside and outside of Japan

* An operating and management company based in the Cayman Islands founded in February 2014, by RC Partners Inc., jointly owned by ReproCELL, and Shinsei Corporate Investment Limited, each with an equity share of 50%.